Prescription drug · ANDA
Glipizide NDC 71335-3133
Glipizide 5 mg/1 · Tablet · Oral · Bryant Ranch Prepack
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 71335-3133-1 | 71335313301 | 100 TABLET in 1 BOTTLE (71335-3133-1)Marketed from May 21, 2026 | |
| 71335-3133-2 | 71335313302 | 30 TABLET in 1 BOTTLE (71335-3133-2)Marketed from May 21, 2026 | |
| 71335-3133-3 | 71335313303 | 60 TABLET in 1 BOTTLE (71335-3133-3)Marketed from May 21, 2026 | |
| 71335-3133-4 | 71335313304 | 90 TABLET in 1 BOTTLE (71335-3133-4)Marketed from May 21, 2026 | |
| 71335-3133-5 | 71335313305 | 20 TABLET in 1 BOTTLE (71335-3133-5)Marketed from May 21, 2026 | |
| 71335-3133-6 | 71335313306 | 180 TABLET in 1 BOTTLE (71335-3133-6)Marketed from May 21, 2026 | |
| 71335-3133-7 | 71335313307 | 10 TABLET in 1 BOTTLE (71335-3133-7)Marketed from May 21, 2026 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Glipizide
- Generic name (nonproprietary)
- glipizide
- Active ingredients
- Glipizide — 5 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Bryant Ranch Prepack
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 074378
- Marketing start
- Listing expires
- Other FDA classes
- Sulfonylurea Compounds (Chemical structure)
- Identifiers
- Product ID 71335-3133_c46ecc12-829e-45b7-adc1-d832a95d429bSPL ID c46ecc12-829e-45b7-adc1-d832a95d429bSPL set ID 9b405ff3-6ce5-460a-9406-db92e0e6ab1bRxCUI 310490UNII X7WDT95N5C
- Pharmacologic class
- Sulfonylurea
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N471335313301followed by a unit qualifier and the quantityPackage 71335-3133-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Glipizide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 074378
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Glipizide | Glipizide 5 mg/1 | TabletOral | Proficient Rx LP | 82804-959 |
| Glipizide | Glipizide 10 mg/1 | TabletOral | Proficient Rx LP | 82804-960 |
| Glipizide | Glipizide 5 mg/1 | TabletOral | Preferred Pharmaceuticals Inc. | 68788-4178 |
| Glipizide | Glipizide 5 mg/1 | TabletOral | Oxford Pharmaceuticals, LLC | 69584-309 |
| Glipizide | Glipizide 10 mg/1 | TabletOral | Oxford Pharmaceuticals, LLC | 69584-310 |
| Glipizide | Glipizide 10 mg/1 | TabletOral | Preferred Pharmaceuticals Inc. | 68788-4061 |